Arsenic in Cancer Treatment: Challenges for Application of Realgar Nanoparticles (A Minireview)

Toxins

Volumn 2, Issue 6, 2010, Pages 1568-1581

  Baláž, Peter ^a   Sedlák, Ján ^b  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

Arsenic sulfide; Cancer; Milling; Nanoparticle; Realgar

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ARSENIC; ARSENIC DERIVATIVE; ARSENIC SULFIDE; ARSENIC TRIOXIDE; BCR ABL PROTEIN; CD11B ANTIGEN; IMATINIB; NANOPARTICLE; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; TETRAARSENIC OXIDE; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ASTHMA; CANCER CHEMOTHERAPY; CHINESE MEDICINE; CHOREA; DNA DAMAGE; DNA FRAGMENTATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG PENETRATION; DRUG SOLUBILITY; ECZEMA; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HODGKIN DISEASE; HUMAN; ISOMERIZATION; LEUKEMIA; LEUKEMIA REMISSION; NONHUMAN; PARTICLE SIZE; PEMPHIGUS; PERNICIOUS ANEMIA; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; SOLID STATE; TRANSCRIPTION REGULATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; HUMANS; NANOPARTICLES; NEOPLASMS; SULFIDES;

EID: 78650835163     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins2061568     Document Type: Review

References (72)

1. Kummar, C.S.S.R. Nanomaterials for Cancer Therapy; WILEY-VCH Verlag: Weinheim, Germany, 2006.
2. Ferrari, M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005, 5, 161-171.
3. Kim, C.K.; Lim, S.J. Recent progress in drug delivery systems for anticancer agents. Arch. Pharm. Res. 2002, 25, 229-239.
4. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 2002, 54, 631-651.
5. Antman, K.H. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 2001, 6 (Suppl. 2), 1-2.
6. Dilda, P.J.; Hogg, P.J. Arsenical-based cancer drugs. Cancer Treat. Rev. 2007, 33, 542-564.
7. Miller, W.H., Jr.; Schipper, H.M.; Lee, J.S.; Singer, J.; Waxman, S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002, 62, 3893-3903.
8. Waxman, S.; Anderson, K.C. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001, 6 (Suppl. 2), 3-10.
9. Wang, Z.Y. Arsenic compounds as anticancer agents. Cancer Chemother. Pharmacol. 2001, 48 (Suppl. 1), S72-S76.
10. Niu, C.; Yan, H.; Yu, T.; Sun, H.P.; Liu, J.X.; Li, X.S.; Wu, W.; Zhang, F.Q.; Chen, Y.; Zhou, L.; et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999, 94, 3315-3324.
11. Soignet, S.L.; Maslak, P.; Wang, Z.G.; Jhanwar, S.; Calleja, E.; Dardashti, L.J.; Corso, D.; DeBlasio, A.; Gabrilove, J.; Scheinberg, D.A.; et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 1998, 339, 1341-1348.
12. Sumi, D.; Shinkai, Y.; Kumagai, Y. Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells. Toxicol. Appl. Pharmacol. 2010, 244, 385-392.
13. Nasr, R.; Lallemand-Breitenbach, V.; Zhu, J.; Guillemin, M.C.; de Thé, H. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin. Cancer Res. 2009, 15, 6321-6326.
14. Park, M.J.; Park, I.C.; Bae, I.J.; Seo, K.M.; Lee, S.H.; Hong, S.I.; Eun, C.K.; Zhang, W.; Rhee, C.H. Tetraarsenic oxide, a novel orally administrable angiogenesis inhibitor. Int. J. Oncol. 2003, 22, 1271-1276.
15. Choi, W.S.; Balaz, P.; Dutkova, E. Mechanochemical preparation of nano-sized pharmaceutical drugs for potential application in cancer therapy: Evaluation of realgar and orpigment as a promising cancer therapeutic agents. In Proceedings of the 3rd Asian Particle Technology Symposium, Beijing, China, 2007.
16. Wu, J.Z.; Ho, P.C. Evaluation of the in vitro activity and in vivo bioavailability of realgar nanoparticles prepared by cryo-grinding. Eur. J. Pharm. Sci. 2006, 29, 35-44.
17. Balaz, P.; Fabian, M.; Pastorek, M.; Cholujova, D.; Sedlak, J. Mechanochemical preparation and anticancer effect of realgar As4S4 nanoparticles. Mater. Lett. 2009, 63, 1542-1544.
18. Wang, L.; Zhou, G.B.; Liu, P.; Song, J.H.; Liang, Y.; Yan, X.J.; Xu, F.; Wang, B.S.; Mao, J.H.; Shen, Z.X.; et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 2008, 105, 4826-4831.
19. Koch, I.; Sylvester, S.; Lai, V.W.; Owen, A.; Reimer, K.J.; Cullen, W.R. Bioaccessibility and excretion of arsenic in Niu Huang Jie Du Pian pills. Toxicol. Appl. Pharmacol. 2007, 222, 357-364.
20. Wu, J.Z.; Ho, P.C. Comparing the relative oxidative DNA damage caused by various arsenic species by quantifying urinary levels of 8-hydroxy-2'-deoxyguanosine with isotope-dilution liquid chromatography/mass spectrometry. Pharm. Res. 2009, 26, 1525-1533.
21. Caple, F.; Williams, E.A.; Spiers, A.; Tyson, J.; Burtle, B.; Daly, A.K.; Mathers, J.C.; Hesketh, J.E. Inter-individual variation in DNA damage and base excision repair in young, healthy non-smokers: effects of dietary supplementation and genotype. Br. J. Nutr. 2010, 1-9.
22. Wei, L.; Liao, P.; Wu, H.; Li, X.; Pei, F.; Li, W.; Wu, Y. Metabolic profiling studies on the toxicological effects of realgar in rats by (1)H NMR spectroscopy. Toxicol. Appl. Pharmacol. 2009, 234, 314-325.
23. Luo, L.Y.; Zhang, T.L.; Wang, K. Differentiation of HL-60 cells induced by realgar nano-particles. Zhongguo Zhong Yao Za Zhi 2006, 31, 1343-1346.
24. Mullen, D.J.E.; Nowacki, W. Refinement of the crystal structure of realgar, AsS and orpigment, As2S3. Zeitschrift für Kristallographie 1972, 136, 48-62.
25. Balaz, P.; Choi, W.S.; Dutkova, E. Mechanochemical modification of properties and reactivity of nanosized arsenic sulfide As4S4. J. Phys. Chem. Solids 2007, 68, 1178-1183.
26. Balaz, P. Mechanochemistry in Nanoscience and Minerals Engineering; Springer: Berlin, Germany, 2008.
27. Bonazzi, P.; Menchetti, S.; Pratesi, G.; Muniz-Miranda, M.; Sbrana, G. Light-induced variations of realgar and betaAs4S4: X-ray diffraction and Raman studies. Am. Mineral. 1996, 81, 874-880.
28. Bonazzi, P.; Bindi, L.; Pratesi, G.; Menchetti, S. Light-induced changes in molecular arsenic sulfides: State of the art and new evidence by single-crystal X-ray diffraction. Am. Mineral. 2006, 91, 1323-1330.
29. Bonazzi, P.; Bindi, L. A crystallographic review of arsenic sulfides: effects of chemical variations and changes induced by exposure to light. Zeitschrift für Kristallographie 2008, 223, 132-147.
30. Bullen, H.A.; Dorko, M.J.; Oman, J.K.; Garrett, S.J. Valence and core-level binding energy shifts in realgar (As4S4) and pararealgar (As4S4) arsenic sulfides. Surf. Sci. 2003, 531, 319-328.
31. Naumov, P.; Makreski, P.; Jovanovski, G. Direct atomic scale observation of linkage isomerization of As4S4 clusters during the photoinduced transition of realgar to pararealgar. Inorg. Chem. 2007, 46, 10624-10631.
32. Macur, R.E.; Jackson, C.R.; Botero, L.M.; McDermott, T.R.; Inskeep, W.P. Bacterial populations associated with the oxidation and reduction of arsenic in an unsaturated soil. Environ. Sci. Technol. 2004, 38, 104-111.
33. Ledbetter, R.N.; Connon, S.A.; Neal, A.L.; Dohnalkova, A.; Magnuson, T.S. Biogenic mineral production by a novel arsenic-metabolizing thermophilic bacterium from the Alvord Basin, Oregon. Appl. Environ. Microbiol. 2007, 73, 5928-5936.
34. Lee, J.H.; Kim, M.G.; Yoo, B.; Myung, N.V.; Maeng, J.; Lee, T.; Dohnalkova, A.C.; Fredrickson, J.K.; Sadowsky, M.J.; Hur, H.G. Biogenic formation of photoactive arsenic-sulfide nanotubes by Shewanella sp. strain HN-41. Proc. Natl. Acad. Sci. USA 2007, 104, 20410-20415.
35. Lu, D.P.; Qiu, J.Y.; Jiang, B.; Wang, Q.; Liu, K.Y.; Liu, Y.R.; Chen, S.S. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 2002, 99, 3136-3143.
36. Lu, D.P.; Wang, Q. Current study of APL treatment in China. Int. J. Hematol. 2002, 76 (Suppl. 1), 316-318.
37. Lu, D.P. Arsenic sulfide compounds and derivates thereof for the treatment of malignancies. US Patent 6,733,792 B1, May 11, 2004.
38. Zhang, C.; Huang, S.L.; Xiang, Y.; Guo, A.X. Study on Realgar inducing apoptosis in T lymphocytic cell line CEM. Zhong Xi Yi Jie He Xue Bao 2003, 1, 42-43.
39. Zhang, J.; Wang, J.C.; Han, Y.H.; Wang, L.F.; Ji, S.P.; Liu, S.X.; Liu, X.P.; Yao, L.B. High expression of bcl-x(L) in K562 cells and its role in the low sensitivity of K562 to realgar-induced apoptosis. Acta Haematol. 2005, 113, 247-254.
40. Wang, H.; Liu, S.; Lu, X.; Zhao, X.; Chen, S.; Li, X. Gene expression profile changes in NB4 cells induced by realgar. Chin. Med. J. (Engl.) 2003, 116, 1074-1077.
41. Zimber, A.; Nguyen, Q.D.; Gespach, C. Nuclear bodies and compartments: functional roles and cellular signalling in health and disease. Cell. Signal. 2004, 16, 1085-1104.
42. Liu, J.; Kadiiska, M.B.; Liu, Y.; Lu, T.; Qu, W.; Waalkes, M.P. Stress-related gene expression in mice treated with inorganic arsenicals. Toxicol. Sci. 2001, 61, 314-320.
43. Basak, S.; Jacobs, S.B.; Krieg, A.J.; Pathak, N.; Zeng, Q.; Kaldis, P.; Giaccia, A.J.; Attardi, L.D. The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation. Mol. Cell 2008, 30, 303-314.
44. Yin, T.; Wu, Y.L.; Sun, H.P.; Sun, G.L.; Du, Y.Z.; Wang, K.K.; Zhang, J.; Chen, G.Q.; Chen, S.J.; Chen, Z. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood 2004, 104, 4219-4225.
45. Wang, M.C.; Liu, S.X.; Liu, P.B. Gene expression profile of multiple myeloma cell line treated by realgar. J. Exp. Clin. Cancer Res. 2006, 25, 243-249.
46. Wang, M.; Liu, S.; Liu, P. Gene expression profile of multiple myeloma cell line treated by arsenic trioxide. J. Huazhong Univ. Sci. Technolog. Med. Sci. 2007, 27, 646-649.
47. Tse, W.P.; Che, C.T.; Liu, K.; Lin, Z.X. Evaluation of the anti-proliferative properties of selected psoriasis-treating Chinese medicines on cultured HaCaT cells. J. Ethnopharmacol. 2006, 108, 133-141.
48. Wang, L.W.; Shi, Y.L.; Wang, N.; Gou, B.D.; Zhang, T.L.; Wang, K. Association of oxidative stress with realgar-induced differentiation in human leukemia HL-60 cells. Chemotherapy 2009, 55, 460-467.
49. Wang, N.; Wang, L.W.; Gou, B.D.; Zhang, T.L.; Wang, K. Realgar-induced differentiation is associated with MAPK pathways in HL-60 cells. Cell Biol. Int. 2008, 32, 1497-1505.
50. Xi, R.G.; Huang, J.; Li, D.; Wang, X.B.; Wu, L.J. Roles of PI3-K/Akt pathways in nanoparticle realgar powders-induced apoptosis in U937 cells. Acta Pharmacol. Sin. 2008, 29, 355-363.
51. Cohen, H.Y.; Miller, C.; Bitterman, K.J.; Wall, N.R.; Hekking, B.; Kessler, B.; Howitz, K.T.; Gorospe, M.; de Cabo, R.; Sinclair, D.A. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004, 305, 390-392.
52. Lunghi, P.; Costanzo, A.; Levrero, M.; Bonati, A. Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells. Blood 2004, 104, 519-525.
53. Verlinden, L.; Verstuyf, A.; Mathieu, C.; Tan, B.K.; Bouillon, R. Differentiation induction of HL60 cells by 1,25(OH)2D3, all trans retinoic acid, rTGF-beta2 and their combinations. J. Steroid Biochem. Mol. Biol. 1997, 60, 87-97.
54. Ujihara, M.; Nomura, K.; Yamada, O.; Demura, H. Establishment of a stable HL60 subline having the potential for monocytic differentiation using granulocyte-macrophage colony-stimulating factor: possible use for the study of monocytic differentiation and oxidative stress. Atherosclerosis 1998, 139, 301-306.
55. Drayson, M.T.; Michell, R.H.; Durham, J.; Brown, G. Cell proliferation and CD11b expression are controlled independently during HL60 cell differentiation initiated by 1,25 alpha-dihydroxyvitamin D(3) or all-trans-retinoic acid. Exp. Cell Res. 2001, 266, 126-134.
56. Luo, L.Y.; Huang, J.; Gou, B.D.; Zhang, T.L.; Wang, K. Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by arsenic sulfide: involvement of serine/threonine protein phosphatases. Leuk. Res. 2006, 30, 1399-1405.
57. Yuksel, S.; Saydam, G.; Uslu, R.; Sanli, U.A.; Terzioglu, E.; Buyukececi, F.; Omay, S.B. Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation. Leuk. Res. 2002, 26, 391-398.
58. Merisko-Liversidge, E.; Liversidge, G.G.; Cooper, E.R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 2003, 18, 113-120.
59. Lee, J. Drug nano- and microparticles processed into solid dosage forms: physical properties. J. Pharm. Sci. 2003, 92, 2057-2068.
60. Kesisoglou, F.; Panmai, S.; Wu, Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. 2007, 59, 631-644.
61. Juillerat-Jeanneret, L. Critical Analysis of Cancer Therapy using Nanomaterials. In Nanomaterials for Cancer Therapy; Kumar, C.S.S.R., Ed.; WILEY-VCH Verlag: Weinheim, Germany, 2006; pp. 199-241.
62. Liversidge, G.G.; Conzentino, P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 1995, 125, 309-313.
63. Liversidge, G.G.; Cundy, K.C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 1995, 125, 91-97.
64. Deng, Y.; Xu, H.; Huang, K.; Yang, X.; Xie, C.; Wu, J. Size effects of realgar particles on apoptosis in a human umbilical vein endothelial cell line: ECV-304. Pharmacol. Res. 2001, 44, 513-518.
65. Ye, H.Q.; Yang, X.L.; Gau, L.; Sun, X.H.; Xu, H.B. Realgar nanoparticles induced cytotoxicity in promyelocytic leukemia HL-60 cells. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2005, 7, 7714-7717.
66. Ye, H.Q.; Gan, L.; Yang, X.L.; Xu, H.B. Membrane toxic ity accounts for apoptosis induced by realgar nanoparticles in promyelocytic leukemia HL-60 cells. Biol. Trace Elem. Res. 2005, 103, 117-132.
67. Ye, H.Q.; Gan, L.; Yang, X.L.; Xu, H.B. Membrane-associated cytotoxicity induced by realgar in promyelocytic leukemia HL-60 cells. J. Ethnopharmacol. 2006, 103, 366-371.
68. Zhao, Q.H.; Zhang, Y.; Liu, Y.; Wang, H.L.; Shen, Y.Y.; Yang, W.J.; Wen, L.P. Anticancer effect of realgar nanoparticles on mouse melanoma skin cancer in vivo via transdermal drug delivery. Med. Oncol. 2009, 27, 203-212.
69. Wang, X.B.; Gao, H.Y.; Hou, B.L.; Huang, J.; Xi, R.G.; Wu, L.J. Nanoparticle realgar powders induce apoptosis in U937 cells through caspase MAPK and mitochondrial pathways. Arch. Pharm. Res. 2007, 30, 653-658.
70. Li, J.E.; Wu, W.L.; Wang, Z.Y.; Sun, G.L. Apoptotic effect of As2S2 on K562 cells and its mechanism. Acta Pharmacol. Sin. 2002, 23, 991-996.
71. Zhao, X.Y.; Li, G.Y.; Liu, Y.; Chai, L.M.; Chen, J.X.; Zhang, Y.; Du, Z.M.; Lu, Y.J.; Yang, B.F. Resveratrol protects against arsenic trioxide-induced cardiotoxicity in vitro and in vivo. Br. J. Pharmacol. 2008, 154, 105-113.
72. Roy, M.; Sinha, D.; Mukherjee, S.; Paul, S.; Bhattacharya, R.K. Protective effect of dietary phytochemicals against arsenite induced genotoxicity in mammalian V79 cells. Indian J. Exp. Biol. 2008, 46, 690-697.